Table 1 |.
Study participant characteristics
| CHARACTERISTIC | N |
|---|---|
| Number of participants | 12 |
| Average age, years (min, max) | 69.4 (52, 83) |
| Age group (years) | |
| ≤ 65 | 3 (25%) |
| 65 – 74 | 5 (41.7%) |
| 75 – 84 | 4 (33.3%) |
| Sex | |
| Female | 9 (75%) |
| Male | 3 (25%) |
| Race | |
| White, non-Hispanic | 9 (75%) |
| White, Hispanic | 1 (8.3%) |
| African American | 1 (8.3%) |
| Asian | 1 (8.3%) |
| Education, years (SD) | 15.3 (2.4) |
| Past medical history | |
| ≤1 Comorbidities | 2 (16.7%) |
| 2+ Comorbidities | 10 (83.3%) |
| Dyslipidemia | 9 (75%) |
| Prediabetes | 4 (33.3%) |
| Diabetes | 2 (16.7%) |
| Hypertension | 6 (50%) |
| Hypothyroidism | 2 (16.7%) |
| Duration of symptoms prior to trial | |
| ≤1 year | 1 (8.3%) |
| 1–2 years | 2 (16.7%) |
| 3+ years | 2 (16.7%) |
| Unknown | 7 (58.3%) |
| Average BMI, kg/m2 (SD) | 25.2 (4.6) |
| Concurrent treatment with donepezil | 7 (58.3%) |